Business Wire

VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment ...

Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Independent valuation analysis estimates post-Phase 3 asset value approaching USD 1 billion, and the current valuation with a ...
Seeking Alpha

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for ...
Morningstar

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in ...
Seeking Alpha

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (FDMT) (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and ...